The following are links to websites that provide an introductions to clinical studies and trials: what they are, how they work, and the services they provide.
The following are links to websites that provide listings and search capability for clinical studies and trials.
TREATMENT OF IDIOPATHIC SHORT STATURE IN CHILDREN (STUDY): Schneider Children’s Hospital is looking for pediatric volunteers to participate in a research study involving a drug for treating Idiopathic short stature (ISS) in Children who don’t grow to a height within the normal range but are otherwise physically normal. You may be eligible to participate in this study if you: Children age 3-9 for females and age 3-10 for males. You may not participate in this study if you: Have a chronic disease
Are pregnant
Have participated in another research study within the last 30 days
For more information,
Kathy Brunner, Study Coordinator,
Biomedical Research Alliance of New York,
Schneider Children’s Hospital,
400 Lakeville Road, Suite 180,
New Hyde Park, NY 11042,
Telephone: 718-470-3290,
Fax: 718-470-4565,
Email:
kbrunner@lij.edu
For children with growth hormone insufficiency are asked to participate in a research study being conducted by Montefiore Medical Center. Your child may be eligible to participate in this study if he/she (1) is between the ages of 3 and 11, and has been diagnosed with growth hormone insufficiency. Your child may not participate in this study if he/she has diabetes or has taken anabolic steroids. Contact Susan Wesoly, Study Coordinator,
Biomedical Research Aliance of New York,
Montefiore Medical Center,
Division of Pediatric Endocrinology,
111 East 210th Street,
Bronx, NY 10467,
Telephone: 718-920-4090.
Fax: 718-405-5609,
Email:
swesoly@msn.com. Massachusetts General Hospital.
PREVALENCE AN METABOLIC CONSEQUENCES OF GROWTH HORMONE DEFICIENCY IN ABDOMINAL OBESITY OVERWEIGHT? (LARGE WAIST (STUDY): If you are 18-55 years old and are over weight with a large waist size, you may qualify for a metabolism research study.
Participants will receive: 2 outpatient visits (4-6 hours each) for blood draws and radiological studies; physical exam; evaluation of growth hormone level; evaluation of your risk of heart disease and of how your body processes sugar; and $100 compensation after completion of the study.
Please call: Hideo Makimura, M.D., Ph.D.
(617) 726-8277.
Precocious Puberty: Marketing Study on the: Current Status and Future Direction of the Precocious Puberty Marketplace. GfK V2, a marketing firm on behalf of a pharmaceutical manufacturer, is conducting a marketing study, using telephone interviews with parents of young patients with precocious puberty, to learn of their (1) experiences and day-to-day issues in the treatment of precocious puberty for their children; (2) views on how the current treatment for precocious puberty could be improved; and (3) views regarding new materials for parents of children with precocious puberty.
To schedule a convenient day and time for the telephone interview, please call 1-888-798-1889. You will be asked several questions to confirm that you qualify to participate in the interview, which will take approximately 45 minutes.
For your participation we are offering an honorarium of $100. The interviews are confidential; and comply with the Code of Standards and Ethics for Survey Research and with HIPAA.
Gene, Brain and Behavior in Turner Syndrome (Children): Turner Girls ages 3-12 years with non-mosaic TS, Nationwide: Genetic factors, brain development and cognitive-behavioral functioning in TS. Participation will involve a 3-4 day evaluation that could include cognitive behavioral evaluation, brain imaging using magnetic resonance imaging (MRI, a non-invasive imaging procedure that does not use x-ray or radiation), and a simple blood test. Benefits of participating include free cognitive and behavioral assessment with a research report of assessment results that can be useful for educational planning, access to ongoing updates about the outcomes of the study, and a $150 honorarium. Travel arrangements will be made by research staff so that there will be no cost to families for participating.
Turner Girls ages 7-12 years: Stanford University Area Only: Cognitive intervention program on improving executive and visual-spatial skills. Participation will involve four weeks of cognitive intervention therapy including a home computer based practice one hour per day, five days per week, one parent training session to ensure effective at-home practice, weekly intervention training sessions under the direction of a licensed clinical neuropsychologist, and post-intervention cognitive evaluation and MRI scan. Benefits of participation include research-based intervention for executive function deficits and a report detailing the results of the neuropsychological evaluation that can be helpful in educational planning.
The studies are being conducted by The Center for Interdisciplinary Brain Sciences Research (CIBSR), Stanford University, http://spnl.stanford.edu. For more information, or to enroll in the study, send email to briad@stanford.edu; or, call toll free: 1-888-411-2672.
IGF-I Study: Recombinant Growth Factor-I (IGF-I) Study: Growth Failure in Noonan Syndrome (Children). The rationale for researching this particular therapy (recombinant human insulin-like growth factor-I (IGF-I), and one of its binding proteins, insulin growth factor binding protein-3 (IGFBP-3), is that it may bypass a problem that could adversely affect the response to growth hormone in children with Noonan syndrome. The study is being carried out to see if giving the study drug for one year will improve the growth of the study population. Children may qualify for the study if they:
- have been diagnosed with Noonan syndrome or are suspected of having Noonan syndrome
- are below a certain height
- are at least 2 years old and not yet in puberty
- are not currently being treated with recombinant human growth hormone
If you are interested in finding out more about our clinical study please visit
www.insmed.com,or share this information with your physician.
A medical market research survey by a UK based market research company is conducting a telephone survey amongst parents of children taking growth hormones. Questions will relate to satisfaction with growth hormones and unmet needs in this therapy area. The interview will be conducted over the phone and will last approx 30 minutes. Each participant will be offered $40 (cheque) to thank them for help and time. A donation will also be made to the Human Growth Foundation.
The survey is conducted for research purposes only -- no sales are involved and no medication will be used. All interviews are treated in complete confidentiality. The survey needs to be completed by the 10th May. If you would like more information or would like to register to take part, please email us, including the following information:
- please quote Project T6334-parents
- age(s) of your child/children taking growth hormones
- your time zone (we are calling from the UK)
- the growth hormone you are using currently (and in the past, if you have changed)
Please email these 2 addresses ASAP (before May the 10th, 2006):
REF5085@fieldworkinternational.com AND
jon.holder@fieldworkinternational.com. You may also call the following toll-free number and leave a message 1-866 382 3839 - Sophie Wintrich, Jon or Lucy (Project T6334 parents)
Research study of children with primary insulin-like growth factor-I deficiency (Primary IGFD). Primary IGFD is characterized by adequate growth hormone, low IGF-I, low growth velocity, and short stature. In primary IGFD, a cellular or genetic defect prevents the body from utilizing growth hormone to produce IGF-I. IGF-I is a principal hormone necessary for statural growth and development. Without IGF-I, the children's bones, cartilage, organs do not grow normally. Clinical trials are currently being conducted throughout the United States to determine the safety and efficacy of recombinant human IGF-1 in children with growth failure due to Primary IGFD.
If your child produces adequate growth hormone, has low IGF-I, but is not growing well, he or she may have Primary IGFD. If you are interested in participating in this study, please call Tercica's Clinical Trials toll-free number at 866-279-9886 to receive information about physicians participating in your area. Children who qualify will receive study medication, medical evaluations and all other study-related procedures at no cost.
